5.60Open5.60Pre Close0 Volume41 Open Interest40.00Strike Price0.00Turnover64.27%IV7.42%PremiumOct 18, 2024Expiry Date2.45Intrinsic Value100Multiplier20DDays to Expiry3.15Extrinsic Value100Contract SizeAmericanOptions Type0.6874Delta0.0555Gamma10.75Leverage Ratio-0.0606Theta0.0138Rho7.39Eff Leverage0.0351Vega
Tandem Diabetes Care Stock Discussion
-- Worldwide GAAP sales increased 13 percent to $221.9 million compared to
second quarter 2023; worldwide non-GAAP sales(1) increased 12 percent to
$221.8 million compared to second quarter 2023.
-- More than 20,000 pumps shipped in the United States, a sequential
increase of 33 percent compared to first quarter 2024.
-- Launched Tandem Mobi with Dexcom G7 continuous glucose monitoring (CGM)
sensor integration in th...
Just check call options. they are expensive
However, stock price moves only 5-10% with no news. Something is going on behind the scene?!
As GLP-1 diet drug companies have grown in influence, they have grown to be the new leaders of the stock market.
$Novo-Nordisk A/S (NVO.US)$ , with Wegovy and Ozempic in hand, is now Europe's largest company with a market capitalization of $433 billion, and the Danish drug giant's rapid growth has even had a direct impact on the Danish krone exchange rate and interest rates.
Meanwhile, $Eli Lilly and Co (LLY.US)$ , whic...
No comment yet